SGLT2 inhibitors have a neutral effect on overall cerebrovascular events but outcomes for stroke following the use of SGLT2 inhibitors differ depending on the stroke subtypes, with a potential benefit for prevention of hemorrhagic stroke. The gene discussed is SLC5A2; the disease is Stroke.